I-MAB Biopharma Co., Ltd.
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
I-Mab Announces Share Purchase Plans by the Company and the Senior Management 2022-08-23 21:13
I-Mab to Report Business and Corporate Updates and Financial Results for the Six Months Ended June 30, 2022 on August 30, 2022 2022-08-19 21:00
I-Mab to Present Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022 2022-07-18 20:00
I-Mab to Host 2022 R&D Day 2022-07-06 20:00
I-Mab Receives Top Rankings in Five Categories by Institutional Investor 2022-06-23 20:00
I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210 2022-06-15 22:37
I-Mab Announces Completion of Patient Enrollment in Phase III Clinical Trial of Eftansomatropin alfa for Treatment of Pediatric Growth Hormone Deficiency 2022-05-31 20:00
I-Mab Reports Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab 2022-05-27 05:01
I-Mab to Hold Investor Call to Report Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab 2022-05-19 20:00
I-Mab Provides Updates on Status under Holding Foreign Companies Accountable Act 2022-05-05 20:00
I-Mab Announces Appointments of Richard Yeh as Chief Operating Officer and John Hayslip as Chief Medical Officer 2022-04-29 04:01
I-Mab Announces Voluntary Lock-ups by Key Shareholders and Senior Management for Long-Term Commitment 2022-03-31 20:00
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Year Ended December 31, 2021 2022-03-29 18:10
I-Mab to Report Full Year 2021 Financial Results and Provide Corporate Update on March 29, 2022 2022-03-18 20:00
I-Mab Provides Updates Regarding Holding Foreign Companies Accountable Act 2022-03-15 20:00
I-Mab Announces Multiple Presentations at the 2022 American Association for Cancer Research (AACR) Annual Meeting 2022-03-09 21:00
I-Mab Receives FDA Orphan Drug Designation for its Novel Claudin 18.2 x 4-1BB Bispecific Antibody TJ-CD4B for the Treatment of Gastric Cancer 2022-03-03 21:00
I-Mab Announces Partnership Agreement to Localize Manufacturing and Accelerate Commercialization of Innovative Biologics Drugs 2022-01-28 21:00
I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Toripalimab in Patients with Advanced Solid Tumors 2022-01-18 21:00
I-Mab Announces Execution of Senior Management Team Share Purchase Plan 2022-01-14 21:00
1 2 3 4 5 9